MRNA vs REGN vs VRTX
161 measures in 16 categories, one definition each, computed from filings and market data.
REGN68.4
Regeneron Pharmaceuticals, Inc.
Healthcare · Biotechnology
$790.74 −0.70%$81.4B mkt cap
Score DNA
VRTX76.1
Vertex Pharmaceuticals Incorporated
Healthcare · Biotechnology
$499.74 −1.77%$126.7B mkt cap
Score DNA
Price, rebased to 100 three years ago
MRNA REGN VRTX · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | MRNA | REGN | VRTX |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 3 | 2 | 2 |
| Last Congress purchase | 2026-09-11 | 2026-07-07 | 2026-09-04 |
| 13F net change in holders | +59 | −58 | +69 |
| ETFs adding shares, 30d | 940 | 1,460 | 1,628 |
| ETFs trimming, 30d | 635 | 1,358 | 1,374 |
| Net ETF funds, 30d | +305 | +102 | +254 |
Valuation
16 measures| Measure | MRNA | REGN | VRTX |
|---|---|---|---|
| P/E (TTM) | — | 18.8x
51st
|
28.8x
59th
|
| PEG (P/E ÷ 3-yr EPS CAGR) | — | 7.83
100th
|
2.86
89th
|
| Price / sales | 39.1x
86th
|
5.2x
28th
|
10.0x
57th
|
| Price / book | 12.9x
82nd
|
2.6x
25th
|
6.3x
70th
|
| Price / tangible book | 4.2x
42nd
|
2.2x
12th
|
6.8x
62nd
|
| Price / free cash flow | — | 23.1x
51st
|
33.4x
63rd
|
| Price / operating cash flow | — | 18.3x
51st
|
29.5x
63rd
|
| Enterprise value | $83.2B
99th
|
$75.4B
99th
|
$120.8B
100th
|
| EV / sales | 37.3x
86th
|
4.9x
36th
|
9.6x
60th
|
| EV / EBITDA | — | 13.1x
38th
|
22.0x
64th
|
| EV / EBIT | — | 14.4x
35th
|
22.9x
55th
|
| EV / free cash flow | — | 21.4x
51st
|
31.8x
63rd
|
| Earnings yield | -3.6%
57th
|
5.3%
86th
|
3.5%
84th
|
| FCF yield | -1.4%
65th
|
4.3%
85th
|
3.0%
81st
|
| Operating cash flow yield | -1.2%
64th
|
5.5%
85th
|
3.4%
81st
|
| Graham number (per share) | — | $520.36
100th
|
$175.20
92nd
|
Profitability (TTM)
12 measures| Measure | MRNA | REGN | VRTX |
|---|---|---|---|
| Gross margin | -12.6%
5th
|
84.9%
47th
|
86.0%
48th
|
| EBITDA margin | -127.0%
34th
|
37.0%
89th
|
43.6%
91st
|
| Operating margin | -149.0%
34th
|
25.6%
84th
|
38.6%
91st
|
| EBIT margin | -137.8%
34th
|
33.6%
88th
|
41.8%
92nd
|
| Net margin | -141.4%
35th
|
27.9%
86th
|
34.9%
89th
|
| NOPAT margin | -117.7%
35th
|
21.4%
82nd
|
32.2%
90th
|
| FCF margin | -54.9%
48th
|
22.7%
84th
|
30.1%
88th
|
| Operating cash flow margin | -47.2%
50th
|
28.6%
87th
|
34.0%
88th
|
| R&D / revenue | 129.1%
69th
|
41.6%
47th
|
31.4%
34th
|
| SG&A / revenue | 43.3%
32nd
|
17.7%
6th
|
15.9%
4th
|
| Stock comp / revenue | 10.1%
36th
|
6.4%
21st
|
5.5%
17th
|
| Effective tax rate | 21.0%
19th
|
16.2%
15th
|
16.5%
15th
|
Returns on capital
11 measures| Measure | MRNA | REGN | VRTX |
|---|---|---|---|
| ROE (on average equity) | -39.0%
37th
|
14.0%
78th
|
23.5%
87th
|
| ROA | -27.4%
36th
|
10.8%
82nd
|
17.1%
86th
|
| ROIC | -90.1%
24th
|
12.9%
56th
|
28.3%
62nd
|
| ROCE | -36.4%
29th
|
14.4%
83rd
|
22.5%
88th
|
| Return on tangible assets | -26.7%
33rd
|
13.1%
82nd
|
20.5%
88th
|
| Cash ROIC (OCF / invested capital) | -36.2%
42nd
|
17.3%
70th
|
29.9%
78th
|
| Gross profitability (GP / assets) | -2.6%
3rd
|
31.6%
54th
|
39.6%
65th
|
| ROIC, 3-yr average | -66.9%
40th
|
14.6%
82nd
|
17.0%
86th
|
| ROIC, 5-yr average | -23.1%
41st
|
22.0%
68th
|
31.9%
72nd
|
| ROE, 5-yr average | -8.5%
77th
|
17.9%
96th
|
17.6%
95th
|
| Incremental ROIC | 15.7%
51st
|
-38.9%
21st
|
29.3%
59th
|
Growth
17 measures| Measure | MRNA | REGN | VRTX |
|---|---|---|---|
| Revenue growth (TTM YoY) | -27.2%
20th
|
9.3%
40th
|
10.6%
41st
|
| Revenue growth (QoQ) | -62.7%
6th
|
19.0%
56th
|
11.6%
44th
|
| Revenue CAGR, 3 yr | -40.5%
6th
|
7.0%
33rd
|
9.9%
35th
|
| Revenue CAGR, 5 yr | -19.7%
8th
|
4.6%
26th
|
13.6%
41st
|
| Gross profit CAGR, 3 yr | — | 7.2%
35th
|
9.1%
37th
|
| Operating income CAGR, 3 yr | — | -4.5%
24th
|
7.1%
29th
|
| Net income growth (TTM YoY) | — | -2.9%
26th
|
21.1%
39th
|
| Net income CAGR, 3 yr | — | 0.2%
31st
|
9.4%
38th
|
| EPS growth (TTM YoY) | — | -1.3%
26th
|
22.6%
39th
|
| EPS CAGR, 3 yr | — | 2.4%
31st
|
10.1%
38th
|
| EPS CAGR, 5 yr | — | -6.3%
20th
|
17.7%
53rd
|
| FCF growth (TTM YoY) | — | -8.4%
14th
|
8.5%
39th
|
| FCF CAGR, 3 yr | — | -5.3%
6th
|
-0.7%
12th
|
| Operating cash flow CAGR, 3 yr | — | -2.1%
6th
|
1.8%
12th
|
| Book value CAGR, 3 yr | -27.3%
23rd
|
12.1%
70th
|
10.1%
69th
|
| Dividend CAGR, 3 yr | — | 29.4% | — |
| Sustainable growth rate | — | 12.8%
23rd
|
23.5%
54th
|
Margin history & stability
7 measures| Measure | MRNA | REGN | VRTX |
|---|---|---|---|
| Gross margin, 3-yr average | 24.2%
12th
|
85.0%
54th
|
86.2%
56th
|
| Operating margin, 3-yr average | -116.0%
51st
|
27.6%
95th
|
23.2%
91st
|
| Net margin, 3-yr average | -117.6%
49th
|
30.4%
93rd
|
20.7%
89th
|
| FCF margin, 3-yr average | -82.8%
53rd
|
24.5%
90th
|
15.8%
84th
|
| Revenue stability (0-1) | 0.48
35th
|
0.87
77th
|
0.99
97th
|
| Earnings stability (0-1) | 0.46
55th
|
0.69
72nd
|
0.09
12th
|
| Margin stability (0-1) | 0.15
35th
|
0.99
96th
|
0.99
94th
|
Liquidity (latest quarter)
7 measures| Measure | MRNA | REGN | VRTX |
|---|---|---|---|
| Cash & short-term investments | $5.1B
98th
|
$8.0B
100th
|
$7.9B
99th
|
| Net cash (− = net debt) | $3.9B
96th
|
$6.0B
100th
|
$5.9B
99th
|
| Working capital | $3.3B
96th
|
$12.9B
100th
|
$8.6B
99th
|
| Current ratio | 2.29
10th
|
3.34
25th
|
3.19
22nd
|
| Quick ratio | 2.18
10th
|
2.78
21st
|
2.74
19th
|
| Cash ratio (cash + ST investments / current liabilities) | 2.03
24th
|
1.45
15th
|
1.99
24th
|
| Defensive interval (days) | 629 days
64th
|
577 days
59th
|
609 days
62nd
|
Leverage & solvency (latest quarter)
13 measures| Measure | MRNA | REGN | VRTX |
|---|---|---|---|
| Total debt | $1.3B
94th
|
$2.0B
96th
|
$2.0B
95th
|
| Debt / equity | 0.19
54th
|
0.06
31st
|
0.10
42nd
|
| Net debt / equity | −0.57
59th
|
−0.19
75th
|
−0.29
72nd
|
| Debt / assets | 11.7%
48th
|
4.8%
27th
|
7.2%
37th
|
| Debt / capital | 16.0%
54th
|
5.9%
31st
|
8.9%
42nd
|
| Debt / EBITDA | — | 0.35
27th
|
0.36
31st
|
| Net debt / EBITDA | — | −1.04
52nd
|
−1.07
48th
|
| Interest coverage (EBIT / interest) | −122.8x
6th
|
94.2x
93rd
|
800.2x
98th
|
| Cash interest coverage | −42.1x
11th
|
80.2x
91st
|
650.4x
98th
|
| Debt payback (years of OCF) | — | 0.4 yrs
34th
|
0.5 yrs
39th
|
| Liabilities / assets | 38.3%
53rd
|
24.0%
36th
|
26.2%
39th
|
| IS credit model rating | BBB+ | AAA | AAA |
| Implied credit spread (bps) | 225
46th
|
50
0th
|
50
0th
|
Efficiency
11 measures| Measure | MRNA | REGN | VRTX |
|---|---|---|---|
| Asset turnover | 0.19
40th
|
0.39
57th
|
0.49
65th
|
| Fixed asset turnover | 0.81
16th
|
2.85
37th
|
3.79
44th
|
| Inventory turnover | 9.6
90th
|
0.7
12th
|
1.1
30th
|
| Receivables turnover | 84.1
97th
|
2.6
12th
|
6.3
52nd
|
| Days sales outstanding | 4 days
8th
|
143 days
89th
|
58 days
51st
|
| Days inventory outstanding | 38 days
10th
|
488 days
88th
|
338 days
70th
|
| Days payables outstanding | 25 days
7th
|
146 days
46th
|
90 days
38th
|
| Cash conversion cycle (days) | 17 days
53rd
|
485 days
94th
|
306 days
87th
|
| Capex / revenue | 7.7%
84th
|
5.9%
78th
|
3.9%
70th
|
| Capex / depreciation | 0.71
68th
|
1.74
85th
|
2.26
92nd
|
| Operating expense ratio | 597.9%
83rd
|
53.5%
18th
|
47.9%
13th
|
Cash flow & earnings quality
7 measures| Measure | MRNA | REGN | VRTX |
|---|---|---|---|
| Operating cash flow / net income | — | 1.03
43rd
|
0.97
41st
|
| FCF / net income | — | 0.81
41st
|
0.86
46th
|
| FCF / operating cash flow | — | 79.3%
18th
|
88.4%
33rd
|
| Capex / operating cash flow | — | 20.7%
82nd
|
11.6%
67th
|
| Accruals ratio | -18.3%
12th
|
-0.3%
71st
|
0.4%
74th
|
| Sloan accruals ratio | -13.6%
17th
|
-2.0%
32nd
|
8.1%
56th
|
| Earnings quality score (0-1) | — | 1.00
81st
|
0.75
38th
|
Scores & forensic checks
15 measures| Measure | MRNA | REGN | VRTX |
|---|---|---|---|
| IS score | 30
36th
|
68
84th
|
76
93rd
|
| IS profitability | 11
4th
|
82
89th
|
96
93rd
|
| IS growth | 24
15th
|
45
27th
|
64
53rd
|
| IS value | 36
51st
|
69
93rd
|
44
79th
|
| IS momentum | 30
14th
|
67
57th
|
80
87th
|
| IS risk (safety) | 100
52nd
|
100
52nd
|
100
52nd
|
| IS quality | 41
32nd
|
85
93rd
|
86
94th
|
| IS balance sheet | 0
0th
|
97
98th
|
97
99th
|
| IS earnings quality | 41
36th
|
68
85th
|
75
95th
|
| IS cash flow | 30
8th
|
69
83rd
|
80
90th
|
| Piotroski F-score (0-9) | 2
4th
|
7
89th
|
6
77th
|
| Altman Z-score | 4.3
54th
|
6.4
67th
|
12.9
81st
|
| Beneish M-score | −4.42
9th
|
−2.31
51st
|
−2.37
49th
|
| Ohlson O-score | −7.37
35th
|
−11.29
7th
|
−11.47
7th
|
| IS credit score | 62
46th
|
97
96th
|
97
96th
|
Size (TTM)
8 measures| Measure | MRNA | REGN | VRTX |
|---|---|---|---|
| Market cap | $87.0B
99th
|
$81.4B
99th
|
$126.7B
100th
|
| Revenue | $2.2B
90th
|
$15.5B
100th
|
$12.6B
99th
|
| EBITDA | −$2.8B
0th
|
$5.8B
100th
|
$5.5B
99th
|
| Net income | −$3.2B
0th
|
$4.3B
99th
|
$4.4B
100th
|
| Free cash flow | −$1.2B
0th
|
$3.5B
99th
|
$3.8B
100th
|
| Total assets | $11.0B
96th
|
$41.7B
100th
|
$27.4B
99th
|
| Shareholders' equity | $6.8B
98th
|
$31.7B
100th
|
$20.2B
99th
|
| Employees | 4,700
97th
|
15,410
100th
|
6,400
98th
|
Price performance
9 measures| Measure | MRNA | REGN | VRTX |
|---|---|---|---|
| 1 day | −7.8% | −0.7% | −1.8% |
| 1 week | −3.1% | +5.9% | −2.0% |
| 1 month | +37.9% | +0.2% | −3.2% |
| 3 months | +266.5% | +17.6% | +4.0% |
| 6 months | +305.8% | +5.3% | +13.3% |
| Year to date | +419.7% | +2.0% | +10.5% |
| 1 year | +796.8% | +37.4% | +22.5% |
| 3 years, cumulative | +101.4% | −4.9% | +36.8% |
| 5 years, cumulative | −45.2% | +44.6% | +179.3% |
Technicals
4 measures| Measure | MRNA | REGN | VRTX |
|---|---|---|---|
| RSI 14 | 61.7 | 57.2 | 43.8 |
| From 52-week high | −10.0% | −8.0% | −10.8% |
| From 52-week low | +878.5% | +40.4% | +24.0% |
| Beta | 0.90 | 0.24 | 0.32 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17